[go: up one dir, main page]

HK1188572A1 - 抗肿瘤生物硷的联合治疗 - Google Patents

抗肿瘤生物硷的联合治疗

Info

Publication number
HK1188572A1
HK1188572A1 HK14101722.7A HK14101722A HK1188572A1 HK 1188572 A1 HK1188572 A1 HK 1188572A1 HK 14101722 A HK14101722 A HK 14101722A HK 1188572 A1 HK1188572 A1 HK 1188572A1
Authority
HK
Hong Kong
Prior art keywords
inhibitors
alkylating agents
combination therapy
anticancer drugs
agents
Prior art date
Application number
HK14101722.7A
Other languages
English (en)
Other versions
HK1188572B (zh
Inventor
Victoria MONEO OCAÑA
Gema Santamaría Núñez
Luis Francisco GARCÍA FERNÁNDEZ
Carlos María GALMARINI
María José GUILLÉN NAVARRO
Pablo Manuel AVILÉS MARÍN
Original Assignee
法马马有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 法马马有限公司 filed Critical 法马马有限公司
Publication of HK1188572A1 publication Critical patent/HK1188572A1/zh
Publication of HK1188572B publication Critical patent/HK1188572B/zh

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41881,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995Pyrazines or piperazines forming part of bridged ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/69Boron compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/243Platinum; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/15Depsipeptides; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
HK14101722.7A 2010-11-12 2011-11-11 抗肿瘤生物硷的联合治疗 HK1188572B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10382300.1 2010-11-12
EP10382300 2010-11-12
PCT/EP2011/069976 WO2012062920A1 (en) 2010-11-12 2011-11-11 Combination therapy with an antitumor alkaloid

Related Parent Applications (4)

Application Number Title Priority Date Filing Date
HK15102911.5A Division HK1202422A1 (zh) 2010-11-12 2014-02-24 抗肿瘤生物硷的联合治疗
HK15102913.3A Division HK1202423B (zh) 2010-11-12 2014-02-24 拓扑异构酶抑制剂的联合治疗
HK15102907.1A Division HK1202421B (zh) 2010-11-12 2014-02-24 抗肿瘤抗生素的联合治疗
HK15102897.3A Division HK1202419B (zh) 2010-11-12 2014-02-24 有丝分裂抑制剂的联合治疗

Related Child Applications (4)

Application Number Title Priority Date Filing Date
HK15102911.5A Addition HK1202422A1 (zh) 2010-11-12 2014-02-24 抗肿瘤生物硷的联合治疗
HK15102913.3A Addition HK1202423B (zh) 2010-11-12 2014-02-24 拓扑异构酶抑制剂的联合治疗
HK15102907.1A Addition HK1202421B (zh) 2010-11-12 2014-02-24 抗肿瘤抗生素的联合治疗
HK15102897.3A Addition HK1202419B (zh) 2010-11-12 2014-02-24 有丝分裂抑制剂的联合治疗

Publications (2)

Publication Number Publication Date
HK1188572A1 true HK1188572A1 (zh) 2014-05-09
HK1188572B HK1188572B (zh) 2017-01-27

Family

ID=

Also Published As

Publication number Publication date
BR122017028568B1 (pt) 2022-03-03
RU2018102078A (ru) 2019-07-19
LT2786756T (lt) 2020-05-11
AU2017276157A1 (en) 2018-01-04
PL2786753T3 (pl) 2019-09-30
US11590129B2 (en) 2023-02-28
HRP20190565T1 (hr) 2019-05-17
ES2719091T3 (es) 2019-07-08
DK2637663T3 (en) 2016-04-18
KR20170124641A (ko) 2017-11-10
ME02395B (me) 2016-09-20
JP2018100303A (ja) 2018-06-28
RU2016144668A (ru) 2018-12-18
EP3666275A3 (en) 2020-09-09
EP2786754A2 (en) 2014-10-08
JP6723815B2 (ja) 2020-07-15
ES2569180T3 (es) 2016-05-09
HK1202419A1 (zh) 2015-10-02
HK1202422A1 (zh) 2015-10-02
BR122017028566B1 (pt) 2022-03-03
DK2786753T3 (en) 2019-04-15
KR20190130078A (ko) 2019-11-20
RU2016144668A3 (zh) 2020-03-25
CN106860870A (zh) 2017-06-20
HRP20200696T1 (hr) 2020-07-24
WO2012062920A1 (en) 2012-05-18
SI2786754T1 (sl) 2019-05-31
KR20130140071A (ko) 2013-12-23
EP2786755A3 (en) 2014-10-29
HK1202423A1 (zh) 2015-10-02
AU2017276155A1 (en) 2018-01-04
ME03408B (me) 2020-01-20
CN103282037A (zh) 2013-09-04
RU2013126630A (ru) 2014-12-20
AU2011328004A1 (en) 2013-05-30
CA2995033A1 (en) 2012-05-18
SI2786756T1 (sl) 2020-07-31
CA2995025C (en) 2020-04-28
CY1121501T1 (el) 2020-05-29
EP2786754B1 (en) 2019-01-09
US20180008602A1 (en) 2018-01-11
ME03501B (me) 2020-04-20
BR112013011480A8 (pt) 2018-01-02
RU2757373C2 (ru) 2021-10-14
KR102247982B1 (ko) 2021-05-04
JP6382516B2 (ja) 2018-08-29
CA2817420C (en) 2019-09-24
SMT201600112B (it) 2016-07-01
CN106860870B (zh) 2020-03-31
EP2637663B1 (en) 2016-02-24
LT2786754T (lt) 2019-04-10
DK2786754T3 (en) 2019-04-15
DK2786756T3 (en) 2020-04-27
AU2016200191A1 (en) 2016-02-04
PT2786753T (pt) 2019-04-24
ES2719052T3 (es) 2019-07-08
KR20160088956A (ko) 2016-07-26
JP2013542241A (ja) 2013-11-21
EP2786755A2 (en) 2014-10-08
JP6724055B2 (ja) 2020-07-15
RU2605335C2 (ru) 2016-12-20
AU2011328004B2 (en) 2016-07-14
CA2995018C (en) 2021-04-20
EP2786753A3 (en) 2014-10-29
HRP20160361T1 (hr) 2016-05-06
HUE042801T2 (hu) 2019-07-29
JP2018100302A (ja) 2018-06-28
TR201904459T4 (tr) 2019-05-21
HRP20190554T1 (hr) 2019-05-03
EP2786756A3 (en) 2014-10-29
PT2786754T (pt) 2019-04-24
EP2786754A3 (en) 2014-10-29
BR122017028570B1 (pt) 2022-03-03
CA2995025A1 (en) 2012-05-18
CY1121504T1 (el) 2020-05-29
EP3666275A2 (en) 2020-06-17
RS58609B1 (sr) 2019-05-31
EP2786756B1 (en) 2020-03-11
RS54648B1 (sr) 2016-08-31
JP6724056B2 (ja) 2020-07-15
HUE027516T2 (en) 2016-10-28
AU2017276155B2 (en) 2019-03-07
AU2016200191B2 (en) 2018-01-18
SI2786753T1 (sl) 2019-05-31
RU2018102080A3 (zh) 2021-04-12
JP2016138133A (ja) 2016-08-04
CA2817420A1 (en) 2012-05-18
EP2786753A2 (en) 2014-10-08
TR201903859T4 (tr) 2019-04-22
EP2786756A2 (en) 2014-10-08
US20180078550A1 (en) 2018-03-22
HK1202421A1 (zh) 2015-10-02
RU2018102078A3 (zh) 2021-04-20
KR20170058454A (ko) 2017-05-26
LT2786753T (lt) 2019-04-10
KR20170057472A (ko) 2017-05-24
AU2017276157B2 (en) 2019-03-07
CA2995033C (en) 2020-04-28
PT2786756T (pt) 2020-05-07
RU2767664C2 (ru) 2022-03-18
CN105664165A (zh) 2016-06-15
SMT201900186T1 (it) 2019-05-10
SMT202000211T1 (it) 2020-05-08
AU2011328004C1 (en) 2017-01-19
CY1117466T1 (el) 2017-04-26
KR20170096065A (ko) 2017-08-23
BR112013011480B1 (pt) 2022-03-22
ES2790414T3 (es) 2020-10-27
US20180078551A1 (en) 2018-03-22
HUE049389T2 (hu) 2020-09-28
BR112013011480A2 (pt) 2016-08-09
RU2018102080A (ru) 2019-07-19
CY1122904T1 (el) 2021-10-29
RS60236B1 (sr) 2020-06-30
CA2995018A1 (en) 2012-05-18
PL2786756T3 (pl) 2020-07-13
PL2637663T3 (pl) 2016-08-31
SMT201900190T1 (it) 2019-05-10
KR102452022B1 (ko) 2022-10-06
RS58608B1 (sr) 2019-05-31
US20230404999A1 (en) 2023-12-21
RU2743643C2 (ru) 2021-02-20
HUE042802T2 (hu) 2019-07-29
US20130266666A1 (en) 2013-10-10
KR20170096224A (ko) 2017-08-23
EP2786753B1 (en) 2019-01-09
SI2637663T1 (sl) 2016-05-31
CN103282037B (zh) 2017-04-05
PL2786754T3 (pl) 2019-07-31
KR102301175B1 (ko) 2021-09-10
KR101716804B1 (ko) 2017-03-15
EP2637663A1 (en) 2013-09-18
KR20210046853A (ko) 2021-04-28

Similar Documents

Publication Publication Date Title
EP3666275A3 (en) Combination therapy with an antitumor alkaloid
WO2012016980A3 (en) Use of sigma ligands in opioid-induced hyperalgesia
WO2014018926A8 (en) Methods and compositions for determining resistance to androgen receptor therapy
PT2716291T (pt) Associação de opióides e fármacos anticancerígenos para o tratamento de cancro
CR20130247A (es) Compuestos tricíclicos de la pi3k y métodos de uso
CL2014003331A1 (es) Formas cristalinas de un modulador de receptor de androgeno
MX2014010590A (es) Terapia de combinacion para trastornos proliferativos.
SG178919A1 (en) Sustituted ( heteroarylmethyl ) thiohydantoins as anticancer drugs
CL2013000016A1 (es) Compuestos derivados de imidazopiridina; procedimiento de preparacion; composicion farmaceutica y su uso en el tratamiento del cancer.
WO2012058241A3 (en) Methods and compositions for ameliorating pancreatic cancer
CL2011001445A1 (es) Compuesto 3-(4-cloro-2-fluorobencil)-2-metil-n-(5-metil-1h-pirazol-3-il)-8-(morfolinometil)imidazo[1,2-b]piridazin-6-amina; composicion farmaceutica; y uso en el tratamiento de trastornos mieloproliferantes cronicos y en el tratamiento de glioblastoma, cancer de amama, mieloma multiple, cancer de prostata y leucemias
TR201203732T1 (tr) Opioid antagonistlerin topikal bileşimleri ve deri hastalıklarının bu bileşimler ile tedavisi için yöntemler.
WO2009140675A3 (en) Combination therapy with pm00104 and another antitumor agent
IN2012DN02149A (zh)
CA2908957C (en) Combination therapy comprising a dihydropyrazino-pyrazine compound and an androgen receptor antagonist for treating prostate cancer
MY160556A (en) Neuregulin antagonists and use thereof in treating cancer
WO2010136168A8 (en) Continuous administration of cilengitide in cancer treatments
MX2010007699A (es) Tratamiento de enfermedades del colon o prevencion de carcinoma colorrectal con derivados de imidazoquinolina.
WO2013177426A3 (en) Targeting the glutamine to pyruvate pathway for treatment of oncogenic kras-associated cancer
JO3145B1 (ar) مركبات مفيدة لتثبيط chk1
WO2013131089A3 (en) Potent anticancer activity via dual compound activation
BR112015005443A2 (pt) tratamento combinado com fármaco interferente de netrina-1 e fármaco quimioterápico
WO2013096335A8 (en) ADMINISTRATION OF AN ANTAGONIST OF α5β1 FOR ANTI-ANTIOGENESIS AND CANCER TREATMENT
WO2012158933A3 (en) Macrocycllc therapeutic agents and methods of treatment
EP2575863A4 (en) USE OF SPARC MICROENVIRONMENT SIGNATURE IN THE TREATMENT OF CANCER